Open AccessCARDIOVASCULAR AUTONOMIC NEUROPATHY: ALPHA-LIPOIC ACID, INSULIN RESISTANCE AND INFLAMMATORY PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Author(s) -
Victoria Serhiyenko,
Мarta Hotsko,
Oksana Snytinska,
Alexandr Serhiyenko
Publication year - 2021
Publication title -
interconf
Language(s) - English
Resource type - Journals
ISSN - 2709-4685
DOI - 10.51582/interconf.21-22.04.2021.037
Subject(s) - insulin resistance , medicine , glycated hemoglobin , type 2 diabetes mellitus , endocrinology , leptin , insulin , diabetes mellitus , type 2 diabetes , homeostatic model assessment , tumor necrosis factor alpha , inflammation , gastroenterology , obesity
This paper presents the results obtained during the study of possible alpha-lipoic acid (ALA) impact on the state of insulin resistance (IR), the content of some pro- and anti-inflammatory factors in patients with type 2 diabetes mellitus (T2DM) and cardiovascular autonomic neuropathy (CAN). Our study involved 33 persons with diagnosed T2DM and CAN, which were allocated to one of two groups. The control group (15 patients) received standard hypoglycemic treatment, whereas the intervention group (18 patients) received ALA 600 mg in film-coated tablets/q.d. in addition to standard therapy. Treatment period was 3 mos in duration. Levels of glycated hemoglobin A1c, glucose, immunoreactive insulin (IRI), leptin, interleukin (IL) IL-6 and IL-8, high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha) in the blood were measured. TNF-alpha/IL-10 ratio and Homeostasis model assessment IR (HOMA-IR) were calculated. The significant reduction in glucose, IRI, leptin concentration and HOMA-IR parameters; decrease in the hs-CRP, TNF-alpha, IL-6 and IL-8 levels, TNF-alpha/IL-10 ratio, with no changes in IL-10 content after 3 mos of treatment was found. The results of our study demonstrated the decrease in the pro-inflammatory link activity after treatment and allow us to consider ALA as one of the promising drug for complex treatment of CAN in patients with T2DM.